DiagnosTear Technologies Inc. News Releases

DiagnosTear Announces Positive Final Results from Clinical Study Demonstrating Strong Diagnostic Performance of TeaRx(TM) Red Eye for Detecting Total Tear IgE as a Biomarker for Allergic conjunctivitis

Thu, 10 Sep 2026 08:30:00 -0400

Final study results demonstrate 89% sensitivity, 83.3% specificity compared with quantitative ELISA reference testing for IgE detection. Vancouver, British Columbia--(Newsfile Corp. - September 10, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), an innovator in point-of-care ocular diagnostics, is pleased to announce positive final results from its clinical study conducted with AlyaTec for TeaRx™ Red Eye further to the Company's press releases dated...

DiagnosTear Technologies Announces FDA Pre-Submission for TeaRx(TM) Red Eye Diagnostic Test

Thu, 03 Sep 2026 07:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - September 3, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a developer of innovative point-of-care eye diagnostic solutions, is pleased to announce the submission of a pre-submission request to the U.S. Food and Drug Administration ("FDA") for its TeaRx™ Red Eye diagnostic test (the "Pre-Submission").The Pre-Submission represents an important regulatory milestone in the Company's U.S. development...

DiagnosTear Technologies Inc. Announces Private Placement of Units

Mon, 31 Aug 2026 07:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - August 31, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") is pleased to announce it will be proceeding with a non-brokered private placement of up to 2,800,000 units ("Units") at a price of C$0.50 per Unit for aggregate gross proceeds of up to C$1,400,000 (the "Offering"). The Company expects BioLight Life Sciences Ltd., parent company of DiagnosTear, and Elcam Medical Ltd. to each participate for up to...

DiagnosTear Announces Interim Clinical Study Results Demonstrating Excellent Correlation Between TeaRx(TM) Red Eye and Quantitative ELISA Testing

Thu, 09 Jul 2026 08:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - July 9, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), an innovator in point-of-care ocular diagnostics, is pleased to announce positive interim analytical results from its ongoing clinical study with AlyaTec for TeaRx™ Red Eye, further to the Company's press releases dated December 2, 2025 and February 26, 2026.Interim results were obtained and analyzed from 30 tear samples originating from the first...

DiagnosTear Achieves Major Scientific Milestone with Publication of TeaRx(TM) Clinical Study in Current Eye Research Journal

Fri, 05 Jun 2026 08:30:00 -0400

Publication in a leading peer-reviewed ophthalmology journal further validates TeaRx™ as a novel point-of-care platform for diagnosis, patient stratification, and prediction of responsiveness to therapy in Dry Eye Disease https://pubmed.ncbi.nlm.nih.gov/42206882/Vancouver, British Columbia--(Newsfile Corp. - June 5, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) ("DiagnosTear" or the "Company"), a leader in developing innovative point-of-care diagnostic solutions for ocular diseases, is...

RETRANSMISSION: DiagnosTear Secures Exclusive Global Rights to CLARIFY Eye Imaging Platform for Needle-Free Blood Diagnostics

Wed, 13 May 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a leader in rapid, eye-based diagnostic technologies, is pleased to announce that on May 12, 2026, it has entered into a definitive exclusive global license agreement for the commercialization of the CLARIFY eye imaging platform, A breakthrough technology enabling blood analysis through a simple eye scan, eliminating the need for needles and...

DiagnosTear Secures Exclusive Global Rights to CLARIFY Eye Imaging Platform for Needle-Free Blood Diagnostics

Tue, 12 May 2026 16:05:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 12, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a leader in rapid, eye-based diagnostic technologies, is pleased to announce that on May 12, 2026, it has entered into a definitive exclusive global license agreement for the commercialization of the CLARIFY eye imaging platform, A breakthrough technology enabling blood analysis through a simple eye scan, eliminating the need for needles and...

DiagnosTear Technologies Inc. Announces Results of AGM

Thu, 07 May 2026 17:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") is pleased to announce results of its annual general meeting of shareholders (the "AGM") held today. Shareholders approved all matters recommended by management, including:Setting the number of directors at five and electing Yaacov Michlin, Julia Reznick Zilberman, Karin Gurevitz, Igal Kohn and John Sinclair as directors of the Company;The appointment...

DiagnosTear Technologies Inc. Announces Warrant Extension

Mon, 04 May 2026 08:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 4, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") announces that it has extended the expiry date of 5,733,885 outstanding common share purchase warrants (the "November 2024 Warrants") and 133,333 outstanding common share purchase warrants (the "December 2024 Warrants"). The November 2024 Warrants were issued in connection with a non-brokered private placement of subscription receipts and in...

DiagnosTear Technologies Inc. Announces Adoption of Semi-Annual Reporting

Tue, 21 Apr 2026 17:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - April 21, 2026) - DiagnosTear Technologies Inc. ("DiagnosTear" or the "Company") announces that it has adopted a semi-annual financial reporting ("SAR") framework, effective immediately. This change is being made pursuant to British Columbia Securities Commission Coordinated Blanket Order 51-933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933").CBO 51-933 allows eligible venture issuers to voluntarily move from a...